You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.
-
Phase II SBIR: Responding to NDM-1- Advancement of a new MBL inhibitor to IND
SBC: VenatoRx Pharmaceuticals, Inc. Topic: NIAIDDESCRIPTION provided by applicant Multi drug resistance in Enterobacteriaceae is regarded as a healthcare crisis While carbapenems are among the most prescribed antibiotics for infections caused by these organisms carbapenem resistance conferred by zinc based metallo carbapenemases Amber Class B is a growing global health concern that threatens to erode the efficacy of these antibiotics both in th ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Preserving beta-lactam utility vs pathogens producing any class of beta-lactamase
SBC: VenatoRx Pharmaceuticals, Inc. Topic: NIAIDDESCRIPTION provided by applicant Multi drug resistance in Enterobacteriaceae is regarded as a healthcare crisis This crisis has been further amplified by the recent emergence of the NDM andquot super bug geneandquot a zinc based metallo lactamase Amber Class B in Enterobacteriaceae Members of this family of resistance enzymes are found on promiscuous plasmids with other MDR resistance mechanisms ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Long-Acting G-CSF Analog for Treating ARS
SBC: BOLDER BIOTECHNOLOGY INC Topic: NIAIDDESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...
SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
